Clinical Trial Update: A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating EndoTAG-1 in combination with paclitaxel and gemcitabine vs paclitaxel and gemcitabine as first-line therapy for visceral metastatic tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• EndoTAG-1
• Gemcitabine (Gemcitabine)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: SynCore Biotechnology Co., Ltd. | Conditions: Triple-Negative Breast Cancer | Phase 3 | Status: SUSPENDED